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Abstract
Introduction: Fatty liver is associated with metabolic syndrome (MetS) but it may also occur without MetS.
Whether resolution of fatty liver in the general population affects risk of MetS is unknown. Our aim was to
determine whether a change in fatty liver status (either the development of new fatty liver or the resolution of
existing fatty liver) would modify the risk of de novo MetS.
Methods: Two thousand eighty-nine people without hypertension, diabetes, and MetS were examined at baseline
and at 5-year follow-up using a retrospective cohort study design. Fatty liver status was assessed at baseline and at
follow-up by ultrasonography. Adjusted hazard ratios (aHR) and 95 % confidence intervals (CIs) for de novo MetS at
follow-up were calculated controlling for the potential confounders, compared to the reference group (people who
never had fatty liver at baseline and follow-up).
Results: During follow-up, fatty liver developed in 251 people and fatty liver resolved in 112 people. After the
adjustment for multiple confounders, persisting fatty liver and incident fatty liver development were associated with
de novo MetS, with aHR of 2.60 (95 % CIs [1.61,4.20]) and 3.31 (95 % CIs [1.99,5.51]), respectively. Risk of new MetS
in resolved fatty liver group was attenuated with insignificant aHR of 1.29 accompanying 95 % CIs of 0.60 and 2.80.
Discussion: Development or maintenance of fatty liver is positively associated with occurrence of new MetS.
Resolution of fatty liver status has similar risk of de novo MetS with those who never had fatty liver. Therefore,
cautious management is needed with those with fatty liver.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is defined as a
disorder with excess fat in the liver due to non-alcoholic
causes [1]. NAFLD is recognized as the most common
cause of liver disease worldwide, with a prevalence of
15–35.8 % in Western populations [2–6], 14–20 % in
Japanese [7], and is more frequent in people with in-
creased amounts of body fat, occurring in up to 85 % in
overweight individuals and 98 % non-diabetic obese
individuals [8].
The metabolic syndrome (MetS) is a cluster of cardio-
metabolic disorders which is known be a risk factor for
development of atherosclerotic cardiovascular disease
and stroke [9]. It occurs in association with central obes-
ity and insulin resistance. The major components of
MetS include insulin resistance, central obesity, dyslipid-
emia, and hypertension [10]. Increased plasma glucose
and triglyceride concentrations are key components of
metabolic syndrome which are overproduced in NAFLD.
The liver is therefore a key determinant of these meta-
bolic abnormalities [1]. NAFLD and MetS are observed
often in the same individual, and insulin resistance is as-
sumed to play a key role that links them together. It is
reported that nearly 90 % of NAFLD patients have more
than one component of metabolic syndrome [11], but it
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is also known that NAFLD can occur in people who do
not have insulin resistance and features of MetS [12].
The severity of fatty liver is associated with increased
cardiovascular risk factors including Mets [13]; however,
it is uncertain whether change in fatty liver status, either
development of new fatty liver or resolution of existing
fatty liver, affects the development of metabolic syn-
drome or not. We have previously investigated relation-
ships between change in fatty liver status and incident
hypertension/diabetes [14, 15]. However, in these studies,
we were not able to adjust waist circumference which was
not available on the whole cohort. Since it is not known
whether change in fatty liver status is associated with de-
velopment of MetS, in this study, we have analyzed the re-
lationship between change in fatty liver status and
development of incident MetS at 5-year follow-up.
Methods
Study population
The study population consisted of individuals who had a
comprehensive health medical examination at baseline
(in 2003) and were re-examined 5 years later (in 2008)
at Kangbuk Samsung Hospital, College of Medicine,
Sungkyunkwan University, South Korea. In South Korea,
employees are required to participate in annual or
biennial health examinations by the industrial safety and
health law. A total of 2174 participants who had waist
circumference data and without hypertension, diabetes,
and metabolic syndrome at baseline were included ini-
tially. Individuals with data missing at baseline for the
following variables were excluded: alcohol consumption
(n = 42), smoking (n = 41), and exercise (n = 18). Some
patients were excluded for more than one reason. There-
fore, 2089 participants were eligible for this analysis.
The examinations were performed without any selec-
tion of high-risk individuals for differential testing. The
institutional review board at Kangbuk Samsung Hospital
has approved the secondary analysis of anonymized data
from the cohort for this study. Informed consent was
not required because personal identifying information
was not used.
Measurement
The health examination included full medical histories,
blood samples, physical examinations, anthropometry,
and abdominal ultrasonography. Body mass index (BMI)
was calculated as weight in kilograms divided by height
in meters squared. Questionnaires were given to exam-
ine to ascertain information regarding alcohol consump-
tion (g/day), smoking (never, ex, current), and frequency
of exercise (none, less than once a week, at least once a
week). Blood samples were collected after at least 10 h
of fasting and analyzed in the same core clinical labora-
tory. The core clinical laboratory has been accredited
and participates annually in inspections and surveys by
the Korean Association of Quality Assurance for Clinical
Laboratories. Triglyceride, high-density lipoprotein chol-
esterol (HDL-C) and fasting plasma glucose, AST, and
ALT were measured using Bayer Reagent packs on an
automated chemistry analyzer (Advia 1650 Autoanayli-
zer; Bayer diagnostics, Leverkusen, Germany). Intra- and
inter-assay coefficients of variation for all biochemical
measurements were <5 %. Insulin concentration was
measured with an immunoradiometric assay (Biosource,
Nivelle, Belgium) with an intra and inter-assay coeffi-
cient of variation of 2.1–4.5 and 4.7–12.2 %, respectively.
Insulin resistance was assessed with the homeostatic
model assessment-insulin resistance (HOMA-IR) ac-
cording to the following equation: Fasting blood insulin
(mU/ml) × Fasting blood glucose (mmol/l)/22.5.
Abdominal ultrasonography (Logic Q700 MR; GE,
Milwaukee, WI, USA) was conducted by clinical radiolo-
gists using a 3.5-MHz probe for all subjects at baseline
and after 5 years. The following images were undertaken:
(1) sagittal view of the right lobe of the liver and right
kidney, (2) transverse view of the left lateral segment of
the liver and spleen, and (3) transverse view of the liver
for altered echo texture. Fatty infiltration of the liver
(fatty liver) was identified if there was an increase in
echogenicity of the liver compared with the echogenicity
of the renal cortex where the diaphragm and intrahepa-
tic vessels appeared normal [16].
The metabolic syndrome definition was used from
the National Cholesterol Education Program (NCEP/
ATP III) [10]. Current ATP III criteria defined the
metabolic syndrome as the presence of any three of the
following five traits: waist circumference in men ≥90 cm
and in women ≥80 cm in Asian patient, serum triglycer-
ides ≥1.7 mmol/L (150 mg/dL) or drug treatment for ele-
vated triglycerides, serum HDL-C <1 mmol/L (40 mg/Dl)
in men and <1.3 mmol/L (50 mg/dL) in women or drug
treatment for low HDL-C, blood pressure ≥130/85 mmHg
or drug treatment for elevated blood pressure, and fasting
plasma glucose (FPG) ≥5.6 mmol/L (100 mg/dL) or drug
treatment for elevated blood glucose.
Statistical analysis
Continuous variables were indicated as mean ± SD for
normally distributed variables or median and interquar-
tile range if variables were not normally distributed.
ANOVA and independent t test were performed to com-
pare continuous variables, and non-normally distributed
variables were compared via Mann-Whitney U and
Kruskal-Wallis tests. Logistic regression was used to de-
termine the hazard ratio (HR) for metabolic syndrome at
follow-up regarding never fatty liver group as the refer-
ence: (a) in patients with resolution of fatty liver over
5 years, i.e., fatty liver that had been present at baseline,
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but was not present at follow-up examination; (b) in pa-
tients with the development of new fatty liver at follow-
up examinations; and (c) in patients with fatty liver that
was present at both baseline and at follow-up. Analyses
were undertaken with the following adjustments. Model
1 was adjusted for age and sex; model 2 for the same
risk factors as model 1 plus alcohol consumption, smok-
ing status, and exercise; and model 3 for the same risk
factors as model 2 plus glucose, waist, systolic blood
pressure, triglyceride, and HDL-C.
All data were analyzed using PASW statistics 18.0
(IBM, Armonk, New York, USA). The statistical signifi-
cance was defined as p value <0.05 (two-tailed).
Results
Two thousand eighty-nine participants were enrolled for
this study, and amongst these subjects, 159 developed
incident metabolic syndrome at 5-year follow-up.
Table 1 shows the baseline characteristics of groups
stratified by the change of fatty liver status: (1) no fatty
liver at baseline nor at follow-up (reference group), (2)
fatty liver at baseline but no fatty liver at follow-up (re-
solved fatty liver group), (3) no fatty liver at baseline but
fatty liver at follow-up (incident fatty liver group), and
(4) fatty liver at both baseline and at follow-up (persisting
fatty liver group). Glucose, triglyceride, HDL-C, BMI,
blood pressure, fasting insulin level, hepatic enzymes, and
HOMA-IR were positively associated with the change of
fatty liver status (p value <0.05, p for trend <0.05).
In each of the four groups, we assessed the num-
bers and percentages of individuals in each of the re-
spective group who developed incident MetS at
follow-up. These data showed 41 (3.1 % of the group
at baseline) for the reference group, 10 (8.9 % of the
group at baseline) for the resolved group, 36 (14.3 %
of the group at baseline) for the incident group, and
72 (18.8 % of the group at baseline) for the persisting
group (Table 2).
We examined the prevalence of MetS components at
baseline and at follow-up in each of the four groups
(Table 2). In the resolved fatty liver group, the propor-
tion of people with increased triglyceride and waist cir-
cumference decreased at follow-up compared with that
at baseline measurements. In contrast, proportion of
people with components of MetS increased in the inci-
dent fatty liver group. The prevalence of MetS was high-
est in persisting fatty liver group (18.8 %), and it was
higher in incident fatty liver group (14.3 %) than the re-
solved fatty liver group (8.9 %).
Table 3 shows hazard ratios for incident MetS at
follow-up, according to the change in fatty liver status.
Persisting fatty liver and incident fatty liver development
were associated with incident MetS, even after the ad-
justment for multiple confounders with aHR of 2.60
(95 % CIs [1.61, 4.20]) and 3.31 (95 % CIs [1.99, 5.51]),
respectively. Risk of incident MetS was attenuated with
insignificant aHR of 1.29 accompanying 95 % CIs as 0.60
and 2.80 in “resolved fatty liver group.”
Table 1 Baseline characteristics of four groups stratified according to the change in fatty liver status
Variables No fatty liver—no fatty
liver (reference group)
(n = 1344)
Fatty liver—no fatty
liver (resolved fatty liver)
(n = 112)
No fatty liver—fatty
liver (incident fatty liver)
(n = 251)
Fatty liver—fatty liver
(persisting fatty liver)
(n = 382)
P value P for
trend
Males (n, %) 822 (61.2 %) 101 (90.2 %) 215 (85.7 %) 361 (94.5 %) <0.001
Age 40.9 ± 6.5 41.9 ± 6.7 41.1 ± 5.6 41.5 ± 5.7 0.210
Glucose (mmol/L) 4.91 ± 0.44 5.05 ± 0.45 5.00 ± 0.44 5.09 ± 0.45 <0.001 0.002
Triglyceride (mmol/L) 1.05 [0.79, 1.42] 1.63 [1.28, 2.09] 1.62 [1.13, 2.06] 1.79 [1.37, 2.42] <0.001 <0.001
HDL-C (mmol/L) 1.54 ± 0.31 1.38 ± 0.25 1.42 ± 0.28 1.36 ± 0.23 <0.001 <0.001
Waist circumference (cm) 76.8 ± 8.3 86.2 ± 5.6 82.6 ± 5.9 87.6 ± 5.3 <0.001 <0.001
BMI (kg/m2) 22.6 ± 2.6 25.2 ± 2.2 24.1 ± 2.2 25.7 ± 2.0 <0.001 <0.001
SBP (mmHg) 109.6 ± 10.1 114.2 ± 8.0 112.4 ± 9.2 114.2 ± 7.8 <0.001 <0.001
DBP (mmHg) 70.5 ± 8.0 73.5 ± 6.4 72.0 ± 7.4 74.0 ± 6.3 <0.001 <0.001
Alcohol 10.45 ± 14.20 11.13 ± 12.44 13.67 ± 16.29 12.27 ± 14.90 0.005 0.367
Smoking status <0.001 <0.001
Never smoker 765 (56.9 %) 37 (33.0 %) 96 (38.2 %) 113 (29.6 %)
Current smoker 579 (43.1 %) 75 (67.0 %) 155 (61.8 %) 269 (70.4 %)
Exercise ≥1/week 555 (41.3 %) 41 (36.6 %) 90 (35.9 %) 125 (32.7 %) 0.014 <0.001
Incident diabetes development 1 (0.1 %) 2 (1.8 %) 3 (1.2 %) 6 (1.6 %) 0.001 <0.001
Data are (n, %) or mean ± SD or median [IQR]. P value was calculated by the ANOVA and independent t test for continuous variables, and Mann-Whitney U and
Kruskal-Wallis tests for non-normally distributed variables
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure
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Table 2 Prevalence of metabolic syndrome components in the four groups at baseline and at follow-up
Metabolic syndrome components
Fatty liver status (n = 1344) Fatty liver status (n = 112) Fatty liver status (n = 251) Fatty liver status (n = 382)
Baseline Follow-up Baseline Follow-up Baseline Follow-up Baseline Follow-up
No fatty liver No fatty liver Fatty liver No fatty liver No fatty liver Fatty liver Fatty liver Fatty liver
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Waist circumference, (men ≥90 cm/women ≥80 cm) 72 (5.4) 110 (8.2) 27 (24.1) 16 (14.3) 28 (11.2) 46 (18.3) 110 (28.8) 108 (28.3)
Triglyceride (TG ≥1.7 mmol/L or drug treatment) 215 (16.0) 213 (15.8) 50 (44.6) 40 (35.7) 112 (44.6) 123 (49.0) 205 (53.7) 202 (52.9)
HDL-C (HDL-C <1 mmol/L (men)/<1.3 mmol/L (women) or drug treatment) 90 (6.7) 100 (7.4) 6 (5.4) 12 (10.7) 19 (7.6) 45 (17.9) 20 (5.2) 52 (13.6)
Blood pressure (BP >130/85 mmHg or drug treatment) 69 (5.1) 172 (12.8) 8 (7.1) 28 (25.0) 16 (6.4) 53 (21.1) 24 (6.3) 99 (25.9)
Glucose (glucose ≥5.6 mmol/L or drug treatment) 106 (7.9) 232 (17.3) 16 (14.3) 37 (33.0) 20 (8.0) 73 (29.1) 59 (15.4) 131 (34.3)
Metabolic syndrome (presence of any three of the following five traits) 0 (0 %) 41 (3.1 %) 0 (0 %) 10 (8.9 %) 0 (0 %) 36 (14.3 %) 0 (0 %) 72 (18.8 %)
Data are (n, %)
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Adjustment of changes in every metabolic component
is illustrated in Table 4. Risk of incident MetS became
insignificant with those adjustments in all groups.
Discussion
Our novel results show that change in fatty liver status
over 5 years is associated with risks of developing MetS
at 5-year follow-up. The development of incident fatty
liver during the 5-year follow-up period was associated
with an increased hazards ratio for incident MetS, and
there was marked attenuation of the risk of MetS with
resolution of fatty liver, which showed similar risk with
the reference group indicating that those without MetS
would be more likely to develop MetS if she/he has new
or persistent NAFLD.
As shown in Table 2, the components of metabolic
syndrome have been improved in “resolved fatty liver
group” but worsened in the “incident fatty liver group.”
Therefore, NAFLD can be considered as alternative way
to describe MetS even though this is not included as a
component of MetS. Definite pathogenic mechanism of
MetS is not clear, and several definitions of MetS exist
[17]. As the current definitions of MetS do not reflect
the entire MetS itself, diagnosis of MetS with NAFLD
would predict metabolic status or risk of certain individ-
uals more precisely. This is the novel data of our study
conducted with individuals without baseline MetS. The
major significance of this study is that those without
MetS would mostly proceed to MetS if she/he has per-
sistent NAFLD. Thus, cautious management of this kind
of subjects is needed.
The mechanism which fatty liver contributes to MetS
is not properly understood but regulation of hepatic
lipid metabolism may be dissociated from the regulation
of glucose metabolism. For example, overexpression of
diacylglycerol acyltransferase 2 (DGAT2) which catalyzes
the final step in triacylglycerol (TG) biosynthesis in the
liver increases hepatic steatosis, manifested as increased
amounts of hepatic TG, diacylglycerol, ceramides, and
unsaturated long-chain fatty acyl-CoAs. Mice overex-
pressing DGAT2 did not have abnormalities of glucose
tolerance or insulin levels [18], supporting the notion
that hepatic steatosis may not necessarily be caused by
insulin resistance.
Why does change in fatty liver status modify risk of
developing MetS? One theory addressing this question
involves the role of hepatokines and inflammatory cyto-
kines that are secreted by the liver which may modulate
metabolic risk and insulin resistance [19, 20]. The liver
secretes many hepatokines. For example, plasminogen-
activator inhibitor-1 is an inflammatory protein that is
secreted by the liver and may affect risk of type 2 dia-
betes [21]. Ardigo et al. found that plasma concentration
of plasminogen-activator inhibitor-1 was only elevated
in individuals with both evidence of insulin resistance
and ultrasound-diagnosed fatty liver and not insulin resist-
ance alone [22]. And inflammatory biomarkers such as C
Table 4 Associations between incident MetS and fatty liver
status derived from a multivariable logistic regression model
containing all variables
HR (95 % CI) P value
Reference group 1 0.81
Resolved fatty liver 0.90 (0.33,2.40) 0.83
Incident fatty liver 1.26 (0.68.2.35) 0.46
Persisting fatty liver 1.22 (0.69.2.14) 0.50
Age 0.99 (0.95.1.02) 0.48
Sex 6.21 (2.58.14.92) <0.001
Alcohol 1.00 (0.99.1.01) 0.84
Smoking 0.83 (0.48.1.43) 0.50
Exercise 1.19 (0.74.1.90) 0.47
Glucose 1.12 (1.09.1.16) <0.001
Triglyceride 1.01 (1.01.1.01) <0.001
HDL-C 0.89 (0.86.0.92) <0.001
Waist circumference 1.16 (1.11.1.21) <0.001
Systolic blood pressure 1.10 (1.06.1.13) <0.001
Change in waist circumference 1.23 (1.16.1.31) <0.001
Change in SBP 1.09 (1.07.1.11) <0.001
Change in glucose 1.10 (1.07.1.13) <0.001
Change in TG 1.01 (1.01.1.01) <0.001
Change in HDL-C 0.90 (0.86.0.93) <0.001
Table 3 Hazard ratios (HRs) for incident metabolic syndrome according to the fatty liver status at baseline and at follow-up
HR [95 % CI]a
No fatty liver—no fatty liver
(reference group)
(n = 1344)
Fatty liver—no fatty liver
(resolved fatty liver)
(n = 112)
No fatty liver—fatty liver
(incident fatty liver)
(n = 251)
Fatty liver—fatty liver
(persisting fatty liver)
(n = 382)
Model 1 1 3.05 [1.47–6.36] 5.34 [3.29–8.65] 7.34 [4.77–11.28]
Model 2 1 3.10 [1.48–6.47] 5.31 [3.27–8.63] 7.42 [4.80–11.47]
Model 3 1 1.29 [0.60–2.80] 3.31 [1.99–5.51] 2.60 [1.61–4.20]
Model 1: adjusted for age and sex; model 2: adjusted for model 1 plus alcohol, smoking status, and exercise; model 3: adjusted for model 2 plus glucose, waist
circumference, systolic blood pressure, triglyceride, and HDL-C
aLogistic regression was used to determine hazard ratio (HR) for developing metabolic syndrome at follow-up
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reactive protein, tumor necrosis factor α, and interleukin-
6 may directly affect risk of some of the MetS components
by adversely affecting hepatic gluconeogenesis, glycogen
synthesis, and insulin signaling [23–26]. These results
might support our results.
Resolution and development of fatty liver disease var-
ies between individuals and is linked to many different
factors which could affect risk of MetS. For example,
variations in diet, physical activity, fluxes of fatty acids,
hepatic oxidative stress, cytokine production, reductions
in very low-density lipoprotein secretion, and alter-
ations in the intestinal microbiome are all associated
with changes in NAFLD [26, 27]. Additionally, in-
creases in free fatty acids (FFA), interleukin (IL)-6,
tumor necrosis factor (TNF)-alpha, together with other
pro-inflammatory cytokines that occur with adipose tis-
sue inflammation and changes in adipose tissue func-
tion are also associated with insulin resistance [28].
Our study has some limitations. Ultrasound has lim-
ited sensitivity to detect low levels of fatty liver and to
detect fatty liver in very obese subjects. However, in this
Asian cohort, there were very few subjects with a BMI
greater than 30 kg/m2 (males 14 and females 3). Further-
more, in this cohort, it was not possible to assess agree-
ment between radiologists in reporting hepatic steatosis
diagnosed by ultrasound, as the ultrasound examination
was undertaken by 18 different sonographers within the
routine clinical service. But inter-observer reliability and
intra-observer reliability for fatty liver diagnosis were
considered substantial (kappa statistic of 0.74) and excel-
lent (kappa statistic of 0.94), respectively, at another
study which was conducted in the same clinic center in
2011 [29]. Finally, we did not consider the severity of
NAFLD in each liver group when classifying the partici-
pants, as the numbers in each group was large enough
to obtain meaningful results.
Conclusion
Development or maintenance of fatty liver is positively
associated with occurrence of new MetS. Resolution of
fatty liver status has similar risk of de novo MetS with
those who never had fatty liver. Therefore, NAFLD is
important as an alternative way to present MetS despite
not included as a component of MetS, and cautious
management is needed with those with fatty liver.
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